
In this episode of Petri Dish Perspectives, we explore Jiangsu Hengrui Pharmaceuticals, the Chinese pharma giant that started as a state-owned generic drug factory in 1970 and quietly became one of the most important drug companies in the world. Over $15 billion in deals with GSK and Novo Nordisk. The world's top clinical trial sponsor. One of the top five drug pipelines globally. All from a city most people can't find on a map.
We break down how Hengrui made the pivot from generics to innovation, why Western pharma is now writing billion-dollar checks for Chinese science, and the controversies, including a scathing FDA warning letter and corruption scandals, that complicate the story.
Because Hengrui wasn't hiding. It was building, the whole time.
🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday!
https://linktr.ee/maneadkhin
#PetriDishPerspectives #Hengrui #ChinaBiotech #Pharma #Biotech #DrugDiscovery #NovoNordisk #GSK #GLP1 #Oncology #LifeSciences #Healthcare #BiotechInnovation #PharmaceuticalIndustry
© 2026 The Perspective Bureau LLC. All rights reserved.
Weitere Episoden von „PETRI DISH PERSPECTIVES“



Verpasse keine Episode von “PETRI DISH PERSPECTIVES” und abonniere ihn in der kostenlosen GetPodcast App.








